RedRidge Bio Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 22

Employees

  • Latest Deal Type
  • Series A

  • Investors
  • 4

RedRidge Bio General Information

Description

Developer of biparatopic antibody therapies designed to enhance efficacy in treating cancer and autoimmune diseases. The company offers precision-engineered antibodies that target two distinct sites on a single protein, enabling healthcare providers to achieve functional inhibition, efficient internalization, and tailored immune modulation for improved patient outcomes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Aeschenvorstadt 36
  • 4051 Basel
  • Switzerland
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Aeschenvorstadt 36
  • 4051 Basel
  • Switzerland

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

RedRidge Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 12-Mar-2025 Completed Startup
1. Early Stage VC 03-Aug-2022 Completed Startup
To view RedRidge Bio’s complete valuation and funding history, request access »

RedRidge Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view RedRidge Bio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

RedRidge Bio Patents

RedRidge Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026052582-A1 Biparatopic antibodies that specifically bind fms related receptor tyrosine kinase 3 Pending 04-Sep-2024

RedRidge Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

RedRidge Bio Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
IDG Capital Venture Capital Minority
Laboratoires Pierre Fabre Corporation Minority
Sixty Degree Capital Venture Capital Minority
New Enterprise Associates Venture Capital Minority
To view RedRidge Bio’s complete investors history, request access »

RedRidge Bio FAQs

  • When was RedRidge Bio founded?

    RedRidge Bio was founded in 2021.

  • Where is RedRidge Bio headquartered?

    RedRidge Bio is headquartered in Basel, Switzerland.

  • What is the size of RedRidge Bio?

    RedRidge Bio has 22 total employees.

  • What industry is RedRidge Bio in?

    RedRidge Bio’s primary industry is Drug Discovery.

  • Is RedRidge Bio a private or public company?

    RedRidge Bio is a Private company.

  • What is RedRidge Bio’s current revenue?

    The current revenue for RedRidge Bio is .

  • How much funding has RedRidge Bio raised over time?

    RedRidge Bio has raised $4.13M.

  • Who are RedRidge Bio’s investors?

    IDG Capital, Laboratoires Pierre Fabre, Sixty Degree Capital, and New Enterprise Associates have invested in RedRidge Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process